Management of New Diagnosed Rectum Cancer in the Course of Acute Myocardial Infarction

Yıl 2018, , 116 - 119, 02.07.2018

Ali Çoner , Davran Çiçek , Sinan Akıncı , Serhat Balcıoğlu , Alp Aydınalp , Haldun Müderrisoğlu

https://doi.org/10.30565/medalanya.383365

Öz

Expected life-spans increase all over the world and in our clinical experience we see atherosclerotic vascular diseases and malignant neoplasms more commonly. Herein, we want to present a case with coexistence of acute myocardial infarction and new diagnosed rectum cancer. Close monitoring is essential in these patients however stent thrombosis can be seen and patient and relatives should be informed about the risks and possible treatment choices in a detailed way. 

Anahtar Kelimeler

Rectum cancer, Myocardial infarction, Antiplatelet therapy

Akut Miyokart Enfarktüsü Seyrinde Yeni Tanı Konulan Rektum Kanseri Yönetimi

Öz

Beklenen yaşam süresi tüm dünyada uzamaktadır ve klinik pratiğimizde aterosklerotik damar hastalıkları ve malign karakterli neoplazmlar günümüzde daha sık görülmektedir. Bu yazımızda, akut miyokart enfarktüsü birlikteliğinde yeni tanı alan rektum kanseri hastamıza yaklaşımımızı aktarmayı amaçladık. Benzer vakalarda yakın monitörizasyon esastır, bununla birlikte stent trombozu olasılığı her zaman göz önünde bulundurulmalıdır, hasta ve hasta yakınları olası tedavi seçenekleri ve riskler konusunda ayrıntılı şekilde bilgilendirilmelidir. 

Anahtar Kelimeler

Rektum kanseri, Miyokard enfarktüsü, Antiplatelet tedavi

Kaynakça

• 1. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000;35:1288-94.
• 2. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Societyof Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014;35:2383-431.
• 3. Huber KC, Evans MA, Bresnahan JF, Gibbons RJ, Holmes DR. Outcome of noncardiac operations in patients with severe coronary artery disease successfully treated preoperatively with coronary angioplasty. Mayo Clin Proc 1992;67:15-21.
• 4. Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA 2013;310:1462-72.
• 5. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, et al. Impact of the everolimus eluting stent on stent thrombosis: a meta analysis of 13 randomized trials. J Am Coll Cardiol 2011;58:1569-77.
• 6. Feres F, Costa RA, Abizaid A, Leon MB, Marin Neto JA, Botelho RV, et al. Three vs. twelve months of dual antiplatelet therapy after zotarolimus eluting stents: the OPTIMIZE rabdomized trial. JAMA2013;310:2510-22.
• 7. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eurointervention 2015;10:1024-94.
• 8. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibiton and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672-84.
• 9. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85.
• 10. Öngen Z. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: What is new?]. Turk Kardiyol Dern Ars. 2018; 46: 1-6. Doi: 10.5543/tkda.2017.77775.